Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported a new stock option grant. On January 16, 2026, he received an employee stock option to purchase 19,932 shares of Incyte common stock at an exercise price of $106.21 per share. These options begin to become exercisable in 37 installments starting January 16, 2026.
The vesting schedule provides that the first 25% of the options vest on July 15, 2026, with the remaining options vesting in monthly installments over the following three years. The option expires on January 15, 2036, giving a ten-year term from the grant date.
Incyte Corporation executive Issa Mohamed Khairie, EVP and Head of US Oncology, reported a new stock option grant. On January 16, 2026, he received an employee stock option giving the right to buy 14,237 shares of Incyte common stock at an exercise price of $106.21 per share, expiring on January 15, 2036. Following this grant, he beneficially owned 14,237 derivative securities directly.
The options begin to become exercisable in 37 installments starting January 16, 2026. The first 25% will vest on July 15, 2026, with the remaining portion vesting monthly over the next three years, tying the long-term incentive to continued service and performance.
Incyte Corporation executive Matteo Trotta, EVP and GM of Dermatology US, reported a grant of employee stock options on common stock. On January 16, 2026, he received 8,542 stock options with an exercise price of $106.21 per share and no cost for the option grant itself. These options expire on January 15, 2036.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining options vesting monthly over the following three years. After this grant, Trotta beneficially owns 8,542 derivative securities directly in the form of these options.
Incyte Corporation’s Principal Accounting Officer, Tray Thomas, reported receiving an employee stock option grant under the company’s equity plan. On January 16, 2026, Thomas was awarded options to purchase 2,425 shares of Incyte common stock at an exercise price of $106.21 per share.
According to the filing, these options begin to vest on January 16, 2026 in 37 installments. The first 25% of the grant vests on July 15, 2026, and the remaining options vest monthly over the following three years. All 2,425 derivative securities are held directly by the reporting officer.
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.
Incyte Corporation EVP Michael James Morrissey, Head of Tech. Operations, reported routine equity compensation activity in company common stock. On January 16, 2026, he received an award of 7,426 restricted stock units (RSUs), which will vest in four equal annual installments of 25% and can be settled one-for-one in common shares. On January 20, 2026, 429 shares were automatically withheld by Incyte at $102.62 per share to cover tax obligations tied to previously granted RSUs. After these transactions, Morrissey beneficially owned 34,250 shares of common stock, including 25,198 shares underlying unvested RSUs and earned performance stock units.
Incyte executive Issa Mohamed Khairie reported two stock transactions. On 01/06/2026, 8,264 shares of common stock were automatically withheld by the issuer at a price of $106.66 to cover tax obligations tied to previously granted restricted stock units. On 01/07/2026, Khairie sold 10,856 shares of Incyte common stock at a price of $109.07 per share in an open market transaction. After these transactions, Khairie directly beneficially owned 66,132 shares of common stock, which includes shares issuable from previously reported RSUs that have not yet vested.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported selling 15,634 shares of Incyte common stock on January 5, 2026 at a price of $101.7 per share. The transaction was reported as a direct sale on a Form 4 insider filing.
After this sale, Stein beneficially owned 34,203 shares of Incyte common stock. This amount includes shares issuable under previously reported restricted stock units and earned performance shares that have been granted but have not yet vested.
A shareholder has filed a notice of proposed sale of 10,856 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. The shares have an aggregate market value of $1,184,050.89 based on the filer’s stated market price.
The filing indicates the securities were acquired on 01/06/2026 as restricted stock directly from the issuer, with the same date shown for payment and the nature of payment listed as not applicable. The notice also reports that 196,322,703 shares of the issuer’s common stock were outstanding at the time of the filing.
Incyte Corporation’s Executive Vice President and Head of Technical Operations reported several sales of company common stock. On December 16, 2025, the officer sold 833 shares at $97.42 per share and 53,175 shares at $97.29 per share. On December 17, 2025, the officer sold 4,323 shares at $97.26 per share. After these transactions, the officer reported beneficial ownership of 27,507 shares, which the filing explains includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.